Oasmia Pharmaceutical AB operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oasmia Pharmaceutical AB with three other
pharmaceutical manufacturers in Europe:
Immunodiagnostic System HDQ
of UNITED KINGDOM
(2020
sales of £39.35 million [US$49.62 million]
of which 59%
was Automated),
Worldwide Healthcare Trust Plc
of UNITED KINGDOM
(£11.02 million [US$13.90 million]
), and
Medincell SA
which is
based in FRANCE
(2.85 million Euros [US$3.23 million]
).
Sales Analysis.
Sales increased substantially in 2020:
Oasmia Pharmaceutical AB reported sales of SEK 201.84 million (US$21.93 million)
for the
fiscal
year ending
April of 2020.
This
represents
an
increase of 10,094.1%
versus 2019, when the company's sales were SEK 1.98 million.